Proteomic patterns in biological fluids: Do they represent the future of cancer diagnostics?

Clinical Chemistry

Volumn 49, Issue 8, 2003, Pages 1272-1275

  Diamandis, Eleftherios P ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; PEPTIDE;

BODY FLUID; CANCER DIAGNOSIS; CANCER SCREENING; DIAGNOSTIC TEST; HUMAN; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PROSTATE CANCER; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; ARTICLE; BLOOD; CHEMISTRY; MALE; NEOPLASM; PROSTATE; PROSTATE TUMOR;

BODY FLUIDS; HUMANS; MALE; MASS SPECTROMETRY; NEOPLASMS; PEPTIDES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0042367739     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.8.1272     Document Type: Review

References (19)

1. Diamandis EP. Tumor markers: past, present and future. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz ML, eds. Tumor markers: physiology, pathobiology, technology, and clinical applications. Washington, DC: AACC Press, 2002:3-8.
2. Diamandis EP, Bruns DE. Cancer diagnostics: discovery and clinical applications. Clin Chem 2002;48:1145-6.
3. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev 2002;1:683-95.
4. Chapman K. The ProteinChip biomarker system from Ciphergen Biosystems: a novel proteomics platform for rapid biomarker discovery and validation. Biochem Soc Trans 2002;30:82-7.
5. Srinivas PR, Srivastava S, Hannah S, Wright GL Jr. Proteomics in early detection of cancer. Clin Chem 2001;47:1901-11.
6. Srinivas PR, Verma M, Zhao Y, Srivastava S. Proteomics for cancer biomarker discovery. Clin Chem 2002;48:1160-9.
7. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002;292:587-92.
8. Petricoin EF III, Ardekani AM, Hitt BA, Levine P, Fusaro VA, Steinberg S, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
9. Petricoin EF III, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576-8.
10. Adam B-L, Qu Y, Davies JW, Ward MD, Clements MA, Cazares LH, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-14.
11. Zhang LJ, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-304.
12. Qu Y, Adam B-L, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminated prostate cancer from nonprostate patients. Clin Chem 2002;48:1835-43.
13. Diamandis EP. Proteomic patterns in serum and identification of ovarian cancer [Letter]. Lancet 2002;360:170.
14. Diamandis EP. Serum proteomic patterns for detection of prostate cancer [Letter]. J Natl Cancer Inst 2003;95:489-90.
15. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-7.
16. Bedzyk WD, Larsen B, Gutteridge S, Ballas RA. Molecular mass determination for prostate-specific antigen and α1-antichymotrypsin complexed in vitro. Biotechnol Appl Biochem 1998;27:249-57.
17. Wright GL Jr, Cazares LH, Leung SM, Nasim S, Adam BL, Yip TT, et al. Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer. Prostatic Dis 1999;2:264-76.
18. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998;35:275-368.
19. Zhang Z. Combining multiple biomarkers in clinical diagnostics - a review of methods and issues. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz ML, eds. Tumor markers: physiology, pathobiology, technology, and clinical applications. Washington, DC: AACC Press, 2002:133-9.